がん臨床試験ジャーナル

Translational Research and Clinical Implications of Pharmacogenomics and Pharmacogenetics in Osteosarcoma

Abstract

Alfredo Zubiar

Pharmacogenomics and pharmacogenetics are burgeoning fields that aim to personalize medicine by tailoring drug treatments based on individual genetic profiles. In osteosarcoma, the most common primary malignant bone tumor in children and adolescents, understanding genetic variations that affect drug response can significantly improve therapeutic outcomes. This article explores the translational studies and clinical impacts of pharmacogenomics and pharmacogenetics in osteosarcoma. It delves into the molecular underpinnings of the disease, reviews current literature on genetic markers associated with drug response, and discusses how these findings can be integrated into clinical practice to enhance treatment efficacy and reduce adverse effects. The convergence of genetic research and clinical application holds promise for more effective and individualized treatments for osteosarcoma patients.